The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01765998 |
Recruitment Status : Unknown
Verified January 2013 by Arnon Blum, The Baruch Padeh Medical Center, Poriya.
Recruitment status was: Not yet recruiting
First Posted : January 11, 2013
Last Update Posted : January 11, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Crohn's Disease | Drug: Probiotic Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation |
Study Start Date : | February 2013 |
Estimated Primary Completion Date : | February 2014 |
Estimated Study Completion Date : | February 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Probiotic
To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.
|
Drug: Probiotic
Clinical evaluation according to the Crohn's activity scale
Other Names:
|
Placebo Comparator: placebo
This will be the comparison group to the experimantal group that recives Probiotic.
|
Drug: Placebo |
- endothelial stem cells [ Time Frame: one year ]to study the ability to create endothelial progenitor stem cells following probiotic management compared to placebo group

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients with Crohns' disease who are stable or have mild acute exacerbations that do not necessitate treatment with systemic corticosteroids
Exclusion Criteria:
- pregnant women, under 18 years or over 60 years,
- patients with known ulcerative colitis,
- patients with any cancer,
- patients with heart failure

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01765998
Israel | |
Baruch Padeh Medical Center | |
Tiberias, Lower galilee, Israel, 15208 |
Principal Investigator: | Arnon Blum, MD | Baruch Padeh Medical Center |
Responsible Party: | Arnon Blum, Doctor, The Baruch Padeh Medical Center, Poriya |
ClinicalTrials.gov Identifier: | NCT01765998 |
Other Study ID Numbers: |
18-2012.CTIL |
First Posted: | January 11, 2013 Key Record Dates |
Last Update Posted: | January 11, 2013 |
Last Verified: | January 2013 |
Crohn's disease, endothelial progenitor cells, probiotic |
Crohn Disease Inflammatory Bowel Diseases Disease Progression Gastroenteritis Gastrointestinal Diseases |
Digestive System Diseases Intestinal Diseases Disease Attributes Pathologic Processes |